Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
Genprex announced positive preclinical data for its lead drug candidate, Reqorsa® Gene Therapy, presented at the 2024 EORTC-NCI-AACR Symposium. The research showed promising results in treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. The company filed two provisional patent applications based on the data for treating mesothelioma and glioblastoma. The presentations, delivered by research collaborators from prestigious institutions including MD Anderson Cancer Center, NYU Langone Health, and UT Health Science Center, focused on TUSC2 gene therapy's potential in treating these challenging cancers.
Genprex ha annunciato dati preclinici positivi per il suo principale candidato farmaceutico, Reqorsa® Gene Therapy, presentati al Simposio EORTC-NCI-AACR 2024. La ricerca ha mostrato risultati promettenti nel trattamento del cancro ai polmoni resistente agli inibitori di Ras, mesotelioma e glioblastoma. L'azienda ha presentato due domande di brevetto provvisorie basate sui dati per il trattamento del mesotelioma e glioblastoma. Le presentazioni, realizzate da collaboratori di ricerca provenienti da istituzioni prestigiose come il MD Anderson Cancer Center, il NYU Langone Health e il UT Health Science Center, si sono concentrate sul potenziale della terapia genica TUSC2 nel trattamento di questi tumori difficili.
Genprex anunció datos preclínicos positivos para su principal candidato a fármaco, Reqorsa® Gene Therapy, presentados en el Simposio EORTC-NCI-AACR 2024. La investigación mostró resultados prometedores en el tratamiento del cáncer de pulmón resistente a inhibidores de Ras, mesotelioma y glioblastoma. La compañía presentó dos solicitudes provisionales de patentes basadas en los datos para el tratamiento de mesotelioma y glioblastoma. Las presentaciones, impartidas por colaboradores de investigación de prestigiosas instituciones, incluyendo el MD Anderson Cancer Center, el NYU Langone Health y el UT Health Science Center, se centraron en el potencial de la terapia génica TUSC2 en el tratamiento de estos tipos de cáncer desafiantes.
Genprex는 2024 EORTC-NCI-AACR 심포지엄에서 발표된 선도 약물 후보인 Reqorsa® 유전자 치료제에 대한 긍정적인 전임상 데이터를 발표했습니다. 연구 결과는 Ras 억제제에 저항성이 있는 폐암, 중피종, 교모세포종 치료에 있어 유망한 결과를 보여주었습니다. 이 회사는 중피종 및 교모세포종 치료를 위한 데이터에 기반하여 두 건의 임시 특허 출원을 제출했습니다. MD Anderson Cancer Center, NYU Langone Health 및 UT Health Science Center와 같은 권위 있는 기관의 연구 협력자들이 발표한 내용은 이러한 어려운 암을 치료하는 데 있어 TUSC2 유전자 치료의 잠재력에 초점을 맞추었습니다.
Genprex a annoncé des données précliniques positives pour son principal candidat médicament, Reqorsa® Thérapie Génique, présentées lors du Symposium EORTC-NCI-AACR 2024. La recherche a montré des résultats prometteurs dans le traitement de cancers pulmonaires résistants aux inhibiteurs de Ras, mésothéliome et glioblastome. L'entreprise a déposé deux demandes de brevet provisoire basées sur les données pour le traitement du mésothéliome et du glioblastome. Les présentations, faites par des collaborateurs de recherche d'institutions prestigieuses telles que le MD Anderson Cancer Center, le NYU Langone Health et le UT Health Science Center, se sont concentrées sur le potentiel de la thérapie génique TUSC2 dans le traitement de ces cancers difficiles.
Genprex gab positive präklinische Daten für seinen Spitzenkandidaten Reqorsa® Gentherapie bekannt, die auf dem 2024 EORTC-NCI-AACR-Symposium präsentiert wurden. Die Forschung zeigte vielversprechende Ergebnisse zur Behandlung von auf Ras-Inhibitoren resistente Lungenkrebs, Mesotheliom und Glioblastom. Das Unternehmen reichte auf der Basis der Daten zwei vorläufige Patentansprüche für die Behandlung von Mesotheliom und Glioblastom ein. Die Präsentationen, die von Forschungspartnern aus angesehenen Institutionen wie dem MD Anderson Cancer Center, dem NYU Langone Health und dem UT Health Science Center gehalten wurden, konzentrierten sich auf das Potenzial der TUSC2-Gentherapie zur Behandlung dieser schwierigen Krebserkrankungen.
- Filing of two new provisional patent applications for mesothelioma and glioblastoma treatments
- Positive preclinical data showing potential effectiveness against multiple cancer types
- Research collaboration with prestigious medical institutions
- Drug candidate still in preclinical stage for mesothelioma and glioblastoma
- No clinical efficacy data presented yet
Insights
The preclinical data presented for REQORSA shows promising potential across multiple hard-to-treat cancers. The therapy's ability to overcome resistance to sotorasib in KRAS G12C mutant lung cancer is particularly significant, as drug resistance remains a major challenge in targeted therapy. The expansion into mesothelioma and glioblastoma represents meaningful diversification of the pipeline.
The filing of two new provisional patents strengthens the company's intellectual property portfolio and potential market opportunities. The formation of a specialized Mesothelioma Clinical Advisory Board with renowned experts indicates serious commitment to advancing this program. However, investors should note that while preclinical data is encouraging, the path to clinical validation and commercialization remains long and uncertain, particularly for a micro-cap company with resources.
Preclinical Data Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
"We are pleased by this promising preclinical data, presented before a prestigious audience of oncology researchers, of REQORSA's potential in serious and difficult to treat cancers including KRAS G12C mutant lung cancer, mesothelioma, and glioblastoma," said Ryan Confer, President and Chief Executive Officer at Genprex. "The role of TUSC2 in lung cancer has been well established, and TUSC2 restoration is being evaluated clinically. However, we are highly encouraged by our preclinical programs expanding the potential use of REQORSA to treat a variety of cancer indications, where patient populations have unmet medical needs."
Genprex has filed two provisional patent applications based on data from two of the presentations. One application involves using REQORSA to treat mesothelioma and the other uses REQORSA to treat glioblastoma. Genprex is a co-owner of the applications along with the respective institutions. TUSC2 is the tumor suppressor gene used in REQORSA. Last month, Genprex announced the formation of its Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-renown researchers from major research institutions specializing in the treatment of mesothelioma.
Featured Genprex-supported posters presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:
Title: "TUSC2 Gene Therapy in KRASG12C Mutant NSCLC Overcomes Acquired Resistance to Sotorasib"
Collaborator: The University of Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372
Title: "TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells"
Collaborator: New York University Langone Health
Catalog Number: 364
Presentation Number: PB352
Title: "Efficacy of Quaratusugene Ozeplasmid (REQORSA) TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas Health Science Center at
Catalog Number: 130
Presentation Number: PB118
To review the posters in detail, please visit Genprex's website, where they are available to download.
About Reqorsa® Gene Therapy
REQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment in inhibitor resistant lung cancer, mesothelioma and glioblastoma; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-mesothelioma-and-glioblastoma-302288226.html
SOURCE Genprex, Inc.
FAQ
What were the key findings from Genprex's (GNPX) preclinical trials presented at the 2024 EORTC-NCI-AACR Symposium?
Which institutions collaborated with Genprex (GNPX) on the 2024 preclinical studies?
What new patent applications did Genprex (GNPX) file based on the 2024 preclinical data?
